Jerry Wolinsky

Emeritus Professor in Neurology

The University of Texas Health Science Center at Houston

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jerry Wolinsky is an Emeritus Professor in Neurology at the University of Texas Health Science Center at Houston. He conducts research focused on multiple sclerosis, including areas such as ethnoracial disparities in gray matter, relapse recovery, and neurofilament light-chain levels in patients. His recent publications highlight the impact of treatment options and disease progression in relapsing-remitting multiple sclerosis. He is dedicated to advancing the understanding of neurodegenerative diseases and improving treatment outcomes.

Articles (13)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Gary Cutter

UNITED STATES

View details

John Lindsey

Professor

The University of Texas Health Science Center at Houston

UNITED STATES

View details

Elias S Sotirchos

Johns Hopkins University

UNITED STATES

View details

Marcus Koch

Associate Professor

University of Calgary

CANADA

View details

Luis Brieva Ruiz

Head of the department

Hospital Universitari Arnau de Vilanova

SPAIN

View details

Kaarina Kowalec

Assistant Professor

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jerry Wolinsky

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

The impact of relapse definition and measures of durability on MS clinical trial outcomes

Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset

Identifying the white matter pathways involved in multiple sclerosis-related tremor using diffusion tensor imaging

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Collaborators (6)

Gary Cutter

John Lindsey

Elias S Sotirchos

Marcus Koch

Luis Brieva Ruiz

Kaarina Kowalec

Make your next move.